VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing

Viking Therapeutics, Inc.

Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.
100% of subjects on 100 mg oral VK2735 reached ≥5% weight loss vs. 0% placebo; GI events mostly mild.
Phase 2 VENTURE: 94% of weight loss maintained 4 weeks post-final dose; supports once-monthly dosing.
78% of prediabetic patients on VK2735 shifted to normoglycemic over 13 weeks vs. 29% on placebo.
Oral Phase 2 to start by year-end 2024; injectable Phase 3 design to be discussed with FDA this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.